Preliminary study finds holographic imaging system promising for cancer treatment planning

November 06, 2006

The device looks like something out of an old science fiction movie, but researchers at Rush University Medical Center in Chicago say it holds promise in the treatment of cancer.

The Perspecta® Spatial 3D system, developed by Actuality Systems, Inc., creates holographic images inside a 24-inch dome. The full-color, full-motion system can display images of the body revealing the exact location of tumors in true 3D space.

A study led by Rush, which also included Tufts-New England Medical Center, and Rhode Island Hospital/Brown Medical School, found the Perspecta has significant potential to achieve better quality in radiation treatment planning. The study results are being presented this week at the annual meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia (November 5-9, 2006).

The effectiveness of radiation therapy depends on the medical team's ability to concentrate high radiation doses to the tumors while minimizing the doses to surrounding critical organs. Many of the planning tasks, such as beam placement, volume delineation, and plan evaluation are three dimensional (3D) in nature. However, current planning displays, showing 2D cross-sections or 3D renderings on a flat computer screen, are two dimensional (2D) in nature.

Actuality Systems "PerspectaRAD" Spatial 3D system generates true 3D imagery with a full 360-degree field of view. Using high-speed electronics, a CT scan is projected onto a screen spinning inside a 24-inch transparent dome. The screen, spinning at over 900 rotations per minute, forms a detailed, holographic image that can be viewed and manipulated from any vantage point around the 360-degree dome, by any number of users.

The study compared radiation treatment plans produced on a flat computer screen with those prepared using the Perspecta. Fourteen previously treated plans were replanned using Perspecta. The plans were then reviewed by four physicians who were unaware of what planning device was used.

All the reviewers felt that the Perspecta device allowed better appreciation of 3D relationships of anatomical and dose data than images from a flat screen display. According to the study, the location and size of over or under-dosed regions were also easier to identify on Perspecta. The reviewers reported that Perspecta produced a better plan in six out of 12 brain cases and was better in the one lung cancer case and one breast cancer case studied.

"Our study found the Perspecta Spatial 3D Display provides users complex information in a more efficient and natural way," said James Chu, PhD, professor and director of medical physics for the department of radiation oncology at Rush. "The preliminary data demonstrates that Perspecta has a significant advantage over current 2D radiation planning systems. We are looking forward to an expanded study with a larger number of patients to determine the true potential of this system."

The Perspecta Spatial 3D System has not received FDA approval and is not intended for use in clinical diagnosis, nor may it be used to prevent, diagnose, or treat disease. In the medical field, Perspecta is offered to qualified research institutions only.
-end-
About Actuality Systems
Actuality Systems, Inc. develops computer assisted surgical planning and guidance products that reduce surgical costs through the integration of proprietary 3-D and 4-D visualization, preoperative planning, and intra-operative guidance and decision support. Actuality's initial products in the area of radiation oncology and soft tissue surgical planning reduce hospital and payer costs by increasing surgical accuracy and reducing time in the operating room, reducing patient impact, and reducing repeat procedures or secondary therapy. The company's flagship product, PerspectaRAD, is a spatial 3-D system that displays images that occupy a volume in space, giving users a 360-degree view and simultaneous multi-view collaboration - without goggles.

About Rush University Medical Center
Rush University Medical Center is an academic health center that encompasses a hospital for adults and children with more than 613 staffed beds, the 61-bed Johnston R. Bowman Health Center for older adult and rehabilitative care, and Rush University. Rush is noted for bringing together clinical care and research to address major health problems, including arthritis and orthopedic disorders, cancer, heart disease, mental illness, neurological disorders and diseases associated with aging. In the recent U.S.News & World Report annual Best Hospitals issue, 10 Rush programs are ranked the among the nation's top 50.

Rush University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.